US › Healthcare

Actuate Therapeutics, Inc. Common stock (ACTU)

US · Healthcare · Biotechnology

$0.60+21.00%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.9M

EPS

$-0.20

EPS estimate

$-0.21

EPS came in at -0.20 against a street estimate of -0.21 — a beat of 4.8%.

Key statistics

Market cap

$11.2M

Forward P/E

0.0

P/B

17.55

Book value

$0.04

EPS (TTM)

$-0.87

52-week high

$8.20

52-week low

$0.41

50-day MA

$1.06

200-day MA

$2.55

Beta

1.20

Analyst view

Analysts rate Actuate Therapeutics, Inc. Common stock a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $11.68.

Shareholding

Insiders

15.41%

Institutions

56.29%

Largest institutional holders

Fund	Stake
Tower Research Capital LLC	0.02%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Actuate Therapeutics, Inc. Common stock — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.